WaveMan · Company
AAWH · Ascend Wellness Holdings, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

AAWH Ascend Wellness (AAWH) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001756390
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Revenue growth
-10.9%
XBRL, annual
Net margin
-23.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$488.3M
four quarters, 2025-07-01 to 2026-06-30
History
FY Dec 2025$500.6M
FY Dec 2024$561.6M
FY Dec 2023$518.6M
FY Dec 2022$405.9M
FY Dec 2021$332.4M
Jun 2026$126.1M
Mar 2026$116.9M
Dec 2025$120.5M
Sep 2025$124.7M
Jun 2025$127.3M
Mar 2025$128.0M
Dec 2024$136.0M
Sep 2024$141.6M
At each fiscal year end
Single quarter
Net margin, TTM
-23.3%
net income over revenue, 2025-07-01 to 2026-06-30
History
FY Dec 2025-23.6%
FY Dec 2024-15.1%
FY Dec 2023-9.3%
FY Dec 2022-19.9%
FY Dec 2021-36.9%
Jun 2026-7.8%
Mar 2026-25.2%
Dec 2025-40.4%
Sep 2025-20.7%
Jun 2025-19.2%
Mar 2025-15.0%
Dec 2024-12.3%
Sep 2024-19.9%
At each fiscal year end
Single quarter
Free cash flow, TTM
-$6.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
History
FY Dec 2025$12.0M
FY Dec 2024$50.8M
FY Dec 2023-$6.3M
FY Dec 2022-$120.0M
FY Dec 2021-$130.2M
Jun 2026$16.7M
Mar 2026-$24.6M
Dec 2025$9.4M
Sep 2025-$8.5M
Jun 2025$11.6M
Mar 2025-$484.0K
Dec 2024$30.1M
Sep 2024-$3.0M
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
History
FY Dec 2025n/a
FY Dec 20244.05x
FY Dec 20232.16x
FY Dec 20222.02x
FY Dec 20211.47x
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025237.29x
Jun 202514.49x
Mar 20256.25x
Dec 20244.05x
Sep 20242.76x
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.05x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
History
FY Dec 20250.13x
FY Dec 20240.26x
FY Dec 20230.24x
FY Dec 2022-0.12x
FY Dec 2021-0.16x
Jun 20260.05x
Mar 20260.04x
Dec 20250.13x
Sep 20250.14x
Jun 20250.15x
Mar 20250.23x
Dec 20240.26x
Sep 20240.23x
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
History
FY Dec 2025-1,004%
FY Dec 2024-79.5%
FY Dec 2023-31.5%
FY Dec 2022-47.6%
FY Dec 2021-136.1%
Jun 2026n/a
Mar 2026n/a
Dec 2025-1,004%
Sep 2025-192.1%
Jun 2025-123.4%
Mar 2025-92.2%
Dec 2024-79.5%
Sep 2024-70.7%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-12.7%
TTM net income over average of 2025-06-30 and 2026-06-30
History
FY Dec 2025-13.1%
FY Dec 2024-9.3%
FY Dec 2023-5.4%
FY Dec 2022-10.1%
FY Dec 2021-21.3%
Jun 2026-12.7%
Mar 2026-14.4%
Dec 2025-13.1%
Sep 2025-9.6%
Jun 2025-9.7%
Mar 2025-9.4%
Dec 2024-9.3%
Sep 2024-9.7%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-1.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
History
FY Dec 2025-2.2%
FY Dec 2024+0.6%
FY Dec 2023-0.5%
FY Dec 2022-1.1%
FY Dec 2021-3.7%
Jun 2026-1.4%
Mar 2026-2.2%
Dec 2025-2.2%
Sep 2025+0.8%
Jun 2025+0.6%
Mar 2025+0.6%
Dec 2024+0.6%
Sep 2024-0.1%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$338.6M
market value at close 2026-10-09 on 2026-08-10 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026$353.3M
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-8.0%
TTM free cash flow over market value at close 2026-10-09
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026-6.8%
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-09. Hover a figure to see how it was computed.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

AAWH Stock Sonar score 4/7 axes

Find similar shapesCompare

AAWH ranks highest on profitability (78th percentile) and financial health (74th), and lowest on growth (34th), among Pharma & Biotech peers.

Profitability
78
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-12.7% · 72 pct, sector of 693
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-1.4% · 85 pct, sector of 578
Financial health
74
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt0.05x · 74 pct, sector of 371
Growth
34
Inputs
  • Revenue growth, YoY-10.9% · 34 pct, sector of 506
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
50
Inputs
  • Short interest, % of float+0.0% · 94 pct, sector of 814
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+39.7% · 5 pct, sector of 512
3 not measured: Insider conviction, Institutional and government, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no insider trades in 180 days; no open-market insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no Congress trades reported
Funds
under five funds report holding it
Revenue
-10.9% year over year
below 66% of Pharma & Biotech
Margin
-23.6% net margin
more than 57% of Pharma & Biotech
Buybacks
$1.6M repurchased, FY to 2025-09-30
below 87% of Pharma & Biotech
Short interest
<0.1% of the float short (float per yahoo 2026-10-09) · 1.0 days to cover · settled 2026-09-30
below 92% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch AAWH

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-55.1%12M
-60%-36%-11%+14%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

Ascend Wellness insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Ascend Wellness Holdings, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-12.

Insider
Filed
Shares
Value
Connolly Brian D
SELL
2024-11-15
325,000
$146.2K
Context
  • First open-market trade here by this insider on our record.
  • The trade is 1.5% of the 21,428,969 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Insider Connolly Brian D sold about $146.2K of AAWH on the open market on Nov 15, 2024, the largest insider sale at the company on our record.
1 transaction on record · a thin record, read with care
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.

Who owns AAWH: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in AAWH

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

AAWH planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$500.6M$561.6M$518.6M$405.9M
Gross profit$169.7M$184.2M$155.1M$134.6M
Operating income$-17.0M$4.7M$-3.6M$-7.5M
Net income$-118.2M$-85.0M$-48.2M$-80.9M
EPS (diluted)-0.58-0.40-0.24-0.44
Operating cash flow$38.1M$73.3M$75.3M$-38.4M
Cash$85.7M$88.3M$72.5M$74.1M
Long-term debt$291.1M$214.4M$297.6M$319.3M
SEC XBRL, fiscal years, as known on 2026-10-12

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies